Background
swapnil hiremath
Metformin- Should I Stay or Should I Go

This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?

Metformin- Should I Stay or Should I Go
Background
Brian Rifkin
KDIGO 2025 ADPKD Guidelines Review

This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD.  These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.


KDIGO 2025 ADPKD Guidelines Review
Background
Cristina Adriana Popa
REGENCY: A B-Cell Super Destroyer in Lupus

This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨

REGENCY: A B-Cell Super Destroyer in Lupus
Background
Cristina Adriana Popa
Hunting Primary Hyperaldosteronism: are MRAs a ...

This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions

Hunting Primary Hyperaldosteronism: are MRAs a blindfold in adrenal vein sampling?
Background
Brian Rifkin
Undercover Aldosterone

This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?

Undercover Aldosterone

Background

Encapsulating Peritoneal Sclerosis: The ISPD Advice

Encapsulating Peritoneal Sclerosis: The ISPD Advice

This week, we will discuss the fresh-off-the-press ISPD guidelines on encapsulating peritoneal sclerosis. We are happy to have support from the ISPD for organizing this - and making the manuscript open, and also the ISPD Vancouver 2018 team, who will be co-hosting the #NephJC chat. 

Can Canaglifozin Communicate Consistency with CANVAS?

Can Canaglifozin Communicate Consistency with CANVAS?

Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes. 

Does Contrast cause acute Kidney Injury?

Does Contrast cause acute Kidney Injury?

Iodinated contrast is well known to cause acute kidney injury (AKI), mainly from its physico-chemical properties, and is the commonly cited as being the third most common cause of AKI in hospitalized patients. But is this really true? Even the term contrast-induced AKI (CI-AKI) is now being increasingly replaced by contrast-associated AKI (CA-AKI), and could contrast be an 'innocent bystander'?